BioCryst Pharmaceuticals, Inc. (BCRX) vs Liquidia Corporation (LQDA)
- BioCryst Pharmaceuticals, Inc. BCRX 7.79 −2.87%
- Liquidia Corporation LQDA 34.35 −1.24%
BioCryst Pharmaceuticals, Inc. and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. Liquidia Corporation is the larger, with a market value of $3.1B against $2.1B — 1.5× the size. BioCryst Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Liquidia Corporation trades at 21.9×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 68.7%. Liquidia Corporation has the higher net margin (30.7% vs −40.9%) and the higher return on invested capital (121.1% vs −610.6%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 9 and Liquidia Corporation on 9.
Valuation
Profitability
| Metric | BCRX | LQDA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.78% | 92.54% | 53.94% |
| Operating margin | (33.29%) | 37.39% | 0.00% |
| Net margin | (40.90%) | 30.74% | 0.00% |
| Free cash flow margin | 39.75% | 33.42% | 0.00% |
| Return on equity | 87.84% | 131.82% | (0.40%) |
| Return on assets | (75.79%) | 35.57% | (3.32%) |
| Return on invested capital | (610.55%) | 121.05% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack